[go: up one dir, main page]

CO2017010621A2 - Compuestos bicíclicos fusionados para el tratamiento de enfermedades - Google Patents

Compuestos bicíclicos fusionados para el tratamiento de enfermedades

Info

Publication number
CO2017010621A2
CO2017010621A2 CONC2017/0010621A CO2017010621A CO2017010621A2 CO 2017010621 A2 CO2017010621 A2 CO 2017010621A2 CO 2017010621 A CO2017010621 A CO 2017010621A CO 2017010621 A2 CO2017010621 A2 CO 2017010621A2
Authority
CO
Colombia
Prior art keywords
diseases
treatment
fused bicyclic
bicyclic compounds
compounds
Prior art date
Application number
CONC2017/0010621A
Other languages
English (en)
Inventor
Raju Mohan
Benjamin Anthony Pratt
Original Assignee
Akarna Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akarna Therapeutics Ltd filed Critical Akarna Therapeutics Ltd
Publication of CO2017010621A2 publication Critical patent/CO2017010621A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En la presente se describen compuestos bicíclicos fusionados, composiciones y método para uso para el tratamiento de enfermedades.
CONC2017/0010621A 2015-03-26 2017-10-18 Compuestos bicíclicos fusionados para el tratamiento de enfermedades CO2017010621A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562138725P 2015-03-26 2015-03-26
PCT/IB2016/000606 WO2016151403A1 (en) 2015-03-26 2016-03-25 Fused bicyclic compounds for the treatment of disease

Publications (1)

Publication Number Publication Date
CO2017010621A2 true CO2017010621A2 (es) 2018-01-31

Family

ID=56072361

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0010621A CO2017010621A2 (es) 2015-03-26 2017-10-18 Compuestos bicíclicos fusionados para el tratamiento de enfermedades

Country Status (16)

Country Link
US (4) US10421759B2 (es)
EP (2) EP3715348A1 (es)
JP (1) JP6843061B2 (es)
KR (1) KR20180003545A (es)
CN (1) CN107912042A (es)
AU (2) AU2016238523A1 (es)
BR (1) BR112017020374A2 (es)
CA (1) CA2980394A1 (es)
CL (1) CL2017002405A1 (es)
CO (1) CO2017010621A2 (es)
HK (1) HK1249756A1 (es)
IL (1) IL254572A0 (es)
MX (1) MX370897B (es)
RU (2) RU2017137366A (es)
SG (2) SG11201707610PA (es)
WO (1) WO2016151403A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016151403A1 (en) * 2015-03-26 2016-09-29 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
CA3025007A1 (en) * 2016-05-25 2017-11-30 Akarna Therapeutics, Ltd. Combination therapies with farnesoid x receptor (fxr) modulators
BR112018074231A2 (pt) * 2016-05-25 2019-03-06 Akarna Therapeutics, Ltd. compostos bicíclicos fundidos para o tratamento de doença
CA3065313A1 (en) * 2017-06-02 2018-12-06 Akarna Therapeutics, Ltd. Fused bicyclic compounds
CN108264474B (zh) * 2018-02-09 2019-10-25 浙江师范大学 一种色胺及其衍生物的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US7595311B2 (en) 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
BRPI0412262A (pt) * 2003-07-23 2006-09-19 X Ceptor Therapeutics Inc derivados de azepina como agentes farmacêuticos
BRPI0514269A (pt) 2004-08-10 2008-06-10 Exelixis Inc compostos heterocìclicos como agentes farmacêuticos
WO2006109633A1 (ja) 2005-04-07 2006-10-19 Daiichi Sankyo Company, Limited 置換インドール化合物
WO2007070796A1 (en) * 2005-12-15 2007-06-21 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
EP2121621B1 (en) 2006-12-08 2014-05-07 Exelixis Patent Company LLC Lxr and fxr modulators
US20090131409A1 (en) 2007-10-22 2009-05-21 Wyeth 1,4,5,6,7,8-HEXAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
US20090137554A1 (en) * 2007-10-22 2009-05-28 Wyeth 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
EP2334681A1 (en) 2008-09-26 2011-06-22 Wyeth LLC 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
MX370480B (es) * 2014-11-21 2019-12-16 Akarna Therapeutics Ltd Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
MX369623B (es) * 2014-12-22 2019-11-14 Akarna Therapeutics Ltd Compuestos biciclicos fusionados para el tratamiento de enfermedades.
WO2016151403A1 (en) * 2015-03-26 2016-09-29 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease

Also Published As

Publication number Publication date
RU2017137366A3 (es) 2019-07-17
CN107912042A (zh) 2018-04-13
AU2020256301A1 (en) 2020-11-05
WO2016151403A1 (en) 2016-09-29
AU2016238523A1 (en) 2017-11-09
JP6843061B2 (ja) 2021-03-17
IL254572A0 (en) 2017-11-30
CL2017002405A1 (es) 2018-04-27
SG10201908881PA (en) 2019-11-28
RU2021107054A (ru) 2021-03-31
RU2017137366A (ru) 2019-04-26
SG11201707610PA (en) 2017-10-30
CA2980394A1 (en) 2016-09-29
BR112017020374A2 (pt) 2018-06-05
US10421759B2 (en) 2019-09-24
EP3715348A1 (en) 2020-09-30
JP2018510876A (ja) 2018-04-19
MX370897B (es) 2020-01-09
US20200079782A1 (en) 2020-03-12
US20180118752A1 (en) 2018-05-03
HK1249756A1 (zh) 2018-11-09
US20210214362A1 (en) 2021-07-15
EP3274350A1 (en) 2018-01-31
MX2017012342A (es) 2018-06-11
US20230002394A1 (en) 2023-01-05
KR20180003545A (ko) 2018-01-09

Similar Documents

Publication Publication Date Title
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
ECSP17063327A (es) Receptores de antígeno quiméricos anti–dll3 y métodos de uso
MX2018003491A (es) Represores de htt y usos de estos.
CO2017004736A2 (es) Péptidos macrociclicos útiles como inmunomoduladores
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016001871A1 (es) Anticuerpos humanos para pd-1
EA201691991A1 (ru) Мультиспецифические антитела
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
AR101905A1 (es) Compuestos bicíclicos
MX389627B (es) Inhibidores de la magl.
MX2016010433A (es) Anticuerpos anti-jagged1 y metodos de uso.
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
MX2017002469A (es) Composiciones de matrices extracelulares.
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
DK3452465T3 (da) Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
BR112017019176A2 (pt) processos para a preparação de fluorocetolídeos
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.